American Journal of BioMedicine
Volume 11, Issue 1, 23 February 2023, Pages 36-44 | http://dx.doi.org/10.18081/2333-5106/2023.11/36
Dimie Aruna 1, Abubakar Adereti 1, 2, Easley A. Munir 1*
Received 12 August 2022 Revised 30 November 2022 Accepted 11 January 2023 Published 23 February 2023
Hepatitis C virus (HCV) is a blood-borne virus that primarily infects the liver and can cause both acute and chronic hepatitis. HCV is one of the leading causes of liver disease worldwide and can lead to cirrhosis, liver failure, and liver cancer if left untreated. Dialysis is the most common reliable and accessible therapeutic approach in end-stage renal disease (ESRD) which increases survival and life expectancy in patients. Despite the screening tests on blood products and devices, nosocomial infections are one of leading causes of morbidity and mortality in ESRD. HCV is more prevalent in ESRD compared to the general population, with an overall prevalence of 9.9% among chronic hemodialysis (CHD) patients in high- and middle-income countries. The objective of this study is to assess the prevalence of occult HCV infection in CHD. All clinical, and demographic data was registered beside blood samples, serological testes and HCV-RNAs from 95 patients; 60.7% were male, with mean age of OCI positive cases was 32.3 ± 14.3 years. Furthermore, three case had detectable viral load which was 54 IU/ml. Inconclusion, there is a risk of OCI among CHD patients that needs follow-up by molecular testing.
Keywords: Hepatitis C virus (HCV); End-stage renal disease; HCV-RNAs
Copyright © 2023 Easley A. Munir, et al. This article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. Lanini S, Easterbrook PJ, Zumla A, Ippolito G. Hepatitis C: global epidemiology and strategies for control. Clin Microbiol Infect 2016; 22(10):833-838.
2. Fejza H, Telaku S. Prevalence of HBV and HCV among blood donors in Kosovo. Virol J 2009; 6:21.
3. Spearman CW, Dusheiko GM, Hellard M, Sonderup M. Hepatitis C. Lancet Lond Engl 2019; 394:1451-1466.
4. Abou Rached A, El Khoury L, El Imad T, Geara AS, Jreijiry J, Ammar W. Incidence and prevalence of hepatitis B and hepatitis C viruses in hemodialysis patients in Lebanon. World J Nephrol 2016; 5:101-107.
5. Botheju WSP, Zghyer F, Mahmud S et al. The epidemiology of hepatitis C virus in Central Asia: systematic review, meta-analyses, and meta-regression analyses. Sci Rep 2019; 9:2090.
6. Soliman AR, Momtaz Abd Elaziz M, El Lawindi MI. Evaluation of an isolation program of hepatitis C virus infected hemodialysis patients in some hemodialysis centers in egypt. ISRN Nephrol 2013; 2013:395467.
7. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45(4):529-538.
8. Gómez-Gutiérrez C, Chávez-Tapia NC, Ponciano-Rodríguez G et al. Prevalence of hepatitis C virus infection among patients undergoing haemodialysis in Latin America. Ann Hepatol 2015; 14:807-814.
9. Blach S, Zeuzem S, Manns M, Altraf I, Dubrog A, Muljono DH, et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2017; 2(3):16176.
10. Sarhan II, Kamel CR. Prevalence of hepatitis C virus seroconversion among hemodialysis patients in Egypt. Egypt Liver J 2015; 5:34-39.
11. Barril G, Quiroga JA, Arenas MD, et al. Impact of isolated hepatitis C virus (HCV) core-specific antibody detection and viral RNA amplification among HCV-seronegative dialysis patients at risk for infection. J Clin Microbiol 2014; 52(8):3053-3056.
12. Stroup DF, Berlin JA, Morton SC et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283:2008-2012.
13. Su Y, Norris JL, Zang C, Peng Z, Wang N. Incidence of hepatitis C virus infection in patients on hemodialysis: a systematic review and meta-analysis. Hemodial Int 2013; 17:532-541.
14. Jadoul M, Barril G. Hepatitis C in hemodialysis: epidemiology and prevention of hepatitis C virus transmission. Contrib Nephrol 2012; 176:35-41.
15. Weber DJ, Rutala WA, Fried MW. Hepatitis C virus outbreaks in hemodialysis centers: a continuing problem. Infect Control Hosp Epidemiol 2016; 37(2):140-142.
16. Sultana C, Oprisan G, Szmal C, et al. Molecular epidemiology of hepatitis C virus strains from Romania. J Gastrointestin Liver Dis 2011; 20(3):261-266. 17. Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health 2019; 22:153-160.
18. Weinstein T, Tur-Kaspa R, Chagnac A, Korzets A, Ori Y, Zevin D, Herman M, Gafter U. Hepatitis C infection in dialysis patients in Israel. Isr Med Assoc J 2001; 3:174-177. 19. Ashkani-Esfahani S, Alavian SM, Salehi-Marzijarani M. Prevalence of hepatitis C virus infection among hemodialysis patients in the middle east: a systematic review and meta-analysis. World J Gastroenterol 2017; 23(1):151-166.
20. Selcuk H, Kanbay M, Korkmaz M, et al. Distribution of HCV genotypes in patients with end-stage renal disease according to type of dialysis treatment. Dig Dis Sci 2006; 51(8):1420-1425.
21. Goodkin DA, Bragg-Gresham JL, Koenig KG, et al. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS) J Am Soc Nephrol 2003; 14:3270-3277.
22. Zehender G, Sorrentino C, Lai A, et al. Reconstruction of the evolutionary dynamics of hepatitis C virus subtypes in Montenegro and the Balkan region. Infect Genet Evol 2013; 17:223-230.
23. Jadoul M, Poignet J-L, Geddes C, et al. The changing epidemiology of hepatitis C virus (HCV) infection in haemodialysis: European multicentre study. Nephrol Dial Transpl 2004; 19:904-909.
24. Bosevska G, Kuzmanovska G, Sikole A, Dzekova-Vidimilski P, Polenakovic M. Screening for hepatitis B, C and HIV infection among patients on haemodialysis (cross sectional analysis among patients from two dialysis units in the period January to July 2005) Prilozi 2009; 30(2):159-174. 25. Alavian SM. A shield against a monster: Hepatitis C in hemodialysis patients. World J Gastroenterol 2009; 15:641-646.
26. Jadoul M, Poignet JL, Geddes C, Locatelli F, Medin C, Krajewska M, et al. The changing epidemiology of hepatitis C virus (HCV) infection in haemodialysis: European multicentre study. Nephrol Dial Transplant 2004; 19(4):904-909.
27. Alter MJ, Lyerla RL, Tokars JI, Miller ER, Arduino MJ. Recommendations for preventing transmission of infections among chronic hemodialysis patients. Morbidity and Mortality Weekly Report: Recommendations and Reports; 2001. pp. 1-43. 28. Al Zabadi H, Rahal H, Fuqaha R. Hepatitis B and C prevalence among hemodialysis patients in the West Bank hospitals, Palestine. BMC Infect Dis 2016; 16:41.
29. Alavian SM. We Need a New National Approach to Control Hepatitis C: It is Becoming too Late. Hepat Mon 2008; 8:165-169. 30. Batchoun RG, Al-Najdawi MA, Al-Taamary S. Anti-ENA antibody profile in hepatitis C patients undergoing hemodialysis. Saudi J Kidney Dis Transpl 2011; 22:682-688.
How to cite this article
Aruna D, Adereti A, Munir EA. Prevalence of hepatitis C virus infection among hemodialysis patients: cohort study. American Journal of BioMedicine 2023; 11(1):36-44.
More Citation Formats
Rights and permissions
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in American Journal of BioMedicine are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.